CMS Medicare GLP-1 Bridge Program Launches July 1st

The CMS press release on the GLP-1 Bridge program:

https://www.cms.gov/newsroom/press-releases/coming-soon-cms-provide-50-monthly-access-glp-1-medications-medicare-beneficiaries

Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries
Press Release-  May 06, 2026

Program Begins July 2026, Expanding Affordable Access to Innovative but Costly Treatments for Seniors

The Centers for Medicare & Medicaid Services (CMS) will provide eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month beginning July 1, 2026, through December 31, 2027.

Under the Medicare GLP-1 Bridge, a time-limited demonstration, CMS is expanding access to innovative, evidence-based weight-loss treatments. Eligible individuals enrolled in Medicare Part D prescription drug plans will be able to access these medications at a predictable and affordable cost—$50 for a monthly supply. This approach reflects CMS’ continued focus on improving access to high-value treatments that support better long-term health outcomes.

“These treatments are a major medical advancement, but too many seniors are currently unable to access them due to high cost,” said CMS Administrator Dr. Mehmet Oz. “The Medicare GLP-1 Bridge changes that by making these medications more affordable and accessible, while advancing our broader goal of helping Americans live healthier lives.”

“GLP-1s can be life-changing for patients managing obesity and related conditions,” said Chris Klomp, Director of Medicare and Chief Counselor at the U.S. Department of Health and Human Services. “This demonstration is designed to make accessing those medications simpler, more predictable, and more consistent across the Medicare program, which means better quality of life for seniors and better value across the health care system.”

The Medicare GLP-1 Bridge operates under the Secretary’s authority to test new approaches to care delivery under Medicare and is supported by CMS, including centralized processes for claims adjudication and payment to pharmacies. This structure allows CMS to expand access while working closely with providers, pharmacies, and other partners to support a consistent and coordinated experience for patients.

What to know before July 1

Beginning July 1, Medicare beneficiaries with Part D coverage may be eligible to access certain GLP-1 medications at $50 for a monthly supply. Beneficiaries can talk to their doctor to determine whether a GLP-1 medication is right for them. CMS will share additional information for beneficiaries as the program begins.

In addition, CMS continues to work with stakeholders—including providers, pharmacies, and manufacturers—to support implementation and ensure all partners have the information they need ahead of launch.

The Medicare GLP-1 Bridge builds on CMS’ broader efforts to improve access to innovative therapies and support healthier outcomes for Medicare beneficiaries. For additional demonstration details, visit:
https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

The Centers for Medicare & Medicaid Services (CMS) Medicare GLP-1 Bridge program is quietly becoming a sensation among seniors. It starts today:

https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge

https://www.reuters.com/legal/litigation/older-americans-left-out-costly-glp-1-craze-expected-flock-new-program-2026-07-01/

Older Americans left out of costly GLP-1 craze expected to flock to new program
By Chris Prentice and Amina Niasse - July 1, 2026

Summary

• Nearly 4 million people expected to qualify, KFF says
• Program creates first obesity-only Medicare coverage pathway
• Wall Street sees program generating billions for drugmakers

NEW YORK, July 1 (Reuters) - Millions more Americans will qualify for obesity medications at just $50 a month under a new Medicare program starting on Wednesday, bringing the highly effective drugs to people aged 65 and older at an affordable price.

The U.S. Centers for Medicare & Medicaid Services' 18-month ​trial program will offer for the first time Novo Nordisk's Wegovy and Eli Lilly's Foundayo and Zepbound as a weight-loss treatment alone.

Medicare, which also covers people with disabilities, has been barred ‌from weight-loss coverage and had paid for the drugs only when prescribed for co-conditions like cardiovascular issues and severe fatty liver disease. Now the program offers three pathways for some Medicare subscribers to qualify for coverage.

Eligible patients are estimated in the single-digit millions, a U.S. official said recently. Wall Street analysts estimate that will amount to billions of dollars in revenue for the drugmakers.

The new price offers a remarkable shift from the last few years, when patients have faced steep out-of-pocket costs for these drugs, with or without ​insurance.

Some doctors and pharmacists who spoke to Reuters warned that the Medicare approval process for the medicines will be slow and complicated. Some doctors also said they were concerned the coverage won't be ​extended after 2027, while eight emphasized that regular follow-up care, a nutrition plan and exercise are particularly important for older people.

"This is a big win. For decades, ⁠medicine has failed to recognize obesity as a disease," said Dr. Christina Nguyen of weight-loss clinic Knownwell in Atlanta. "Even with (program) restrictions, we'll be able to offer medications to many patients for the first time."

PATIENTS MORE THAN READY

Katie ​Smith, 71, a retired teacher in Manassas, Virginia, said her doctor prescribed a GLP-1, but the cost at her pharmacy was prohibitive.

"The quote is $1,298.99. Medicare won't cover it, because I'm not diabetic or have sleep apnea," she said ​of conditions that are covered.
Smith said she has limited mobility after a spinal cord injury from a car accident in her 20s. She uses a walker, has weakness on one side and permanent nerve damage.

"It's not good to be carrying this extra weight around. They say it's diet and exercise. I've tried it all," she said. "It could be that I won't tolerate (a GLP-1), but I would so like to try it."

Sandi Henderson, 77, of Oxnard, California, previously had lap-band surgery, but had to have the ​band removed following issues. She now takes a compounded GLP-1 because she cannot afford branded drugs, which sell for $149 to $399 a month for cash through the companies, or more at retail pharmacies.

"I'm thrilled. The ability to have ​this drug accessible to people who haven't been able to afford it - just wow, it brings tears to my eyes," Henderson said in a phone interview. "Then add to that, we're going to save $1,000 plus that we can invest in other ‌forms of our ⁠health."

PENT-UP DEMAND

Executives from Eli Lilly and Novo Nordisk have pointed to estimates of as many as 20 million people qualifying for the program, though health research organization KFF this week said nearly 4 million would be eligible, based on 2023 data.

A CMS spokesperson declined to provide specific enrollment expectations, but Medicare Director Chris Klomp has estimated eligibility to be in the single-digit millions.

There is no shortage of pent-up demand. Yale Medicine obesity specialist Dr. Jorge Moreno said he has had some patients reschedule appointments to July, after the pilot program has launched.

"There is a lot of excitement already from patients," he said. "I've been getting messages on an almost daily basis."

Knownwell's Nguyen said her practice ​has hired additional clinicians and prepared patients to expect ​signing up could take "a couple of weeks or ⁠more" for pre-authorization.

Two pharmacy trade organizations said they expect snags in the program's implementation due to the mid-year launch, with little time for pharmacists to learn about the details and the requirement of prior authorization from prescribing clinicians.

They and a third trade group expect pharmacies to keep limited inventories of the expensive GLP-1 drugs. That could ​lead to increased wait times for patients, they said.

FOLLOW-UP AND RISKS

development, but older adults should approach GLP-1 therapy as part of ​a comprehensive obesity-care plan, not as ⁠a stand-alone medication," said Dr. John Batsis, a geriatric specialist at University of North Carolina. "For older adults, the main concern is not simply pounds lost, but what type of weight is lost."

With the rise of GLP-1 medications, concerns have mounted over the potential loss of muscle mass, and if weight is regained, whether it is as fat or muscle.

One of the biggest risks is the temporary nature of the program, said Dr. Elbert Huang, a primary care physician and director ⁠of University of ​Chicago's Center for Chronic Disease Research and Policy.

If the pilot works well it could become a bridge to enhanced coverage by insurers who ​have expressed reservations about the program.
"To me, the big scientific uncertainty is how long does one need to stay on the drugs to reap the benefits of the weight loss?" Huang said. "If you're someone signing up for this program, which is only in place temporarily, what ​happens after 2027?"

The entire Bridge program will probably cost less than one year's Medicaid fraud in Minnesota.